Effect of Colchicine on Myocardial Injury in Acute Myocardial Infarction
Nathan Mewton,François Roubille,Didier Bresson,Cyril Prieur,Claire Bouleti,Thomas Bochaton,Fabrice Ivanes,Olivier Dubreuil,Loïc Biere,Ahmad Hayek,François Derimay,Mariama Akodad,Benjamin Alos,Lamis Haider,Naoual El Jonhy,Rachel Daw,Charles De Bourguignon,Carole Dhelens,Gérard Finet,Eric Bonnefoy-Cudraz,Gabriel Bidaux,Florent Boutitie,Delphine Maucort-Boulch,Pierre Croisille,Gilles Rioufol,Fabrice Prunier,Denis Angoulvant
DOI: https://doi.org/10.1161/CIRCULATIONAHA.121.056177
IF: 37.8
2021-09-14
Circulation
Abstract:Background: Inflammation is a key factor of myocardial damage in reperfused ST-segment-elevation myocardial infarction. We hypothesized that colchicine, a potent anti-inflammatory agent, may reduce infarct size (IS) and left ventricular (LV) remodeling at the acute phase of ST-segment-elevation myocardial infarction. Methods: In this double-blind multicenter trial, we randomly assigned patients admitted for a first episode of ST-segment-elevation myocardial infarction referred for primary percutaneous coronary intervention to receive oral colchicine (2-mg loading dose followed by 0.5 mg twice a day) or matching placebo from admission to day 5. The primary efficacy outcome was IS determined by cardiac magnetic resonance imaging at 5 days. The relative LV end-diastolic volume change at 3 months and IS at 3 months assessed by cardiac magnetic resonance imaging were among the secondary outcomes. Results: We enrolled 192 patients, 101 in the colchicine group and 91 in the control group. At 5 days, the gadolinium enhancement-defined IS did not differ between the colchicine and placebo groups with a mean of 26 interquartile range (IQR) [16-44] versus 28.4 IQR [14-40] g of LV mass, respectively (P=0.87). At 3 months follow-up, there was no significant difference in LV remodeling between the colchicine and placebo groups with a +2.4% (IQR, -8.3% to 11.1%) versus -1.1% (IQR, -8.0% to 9.9%) change in LV end-diastolic volume (P=0.49). Infarct size at 3 months was also not significantly different between the colchicine and placebo groups (17 IQR [10-28] versus 18 IQR [10-27] g of LV mass, respectively; P=0.92). The incidence of gastrointestinal adverse events during the treatment period was greater with colchicine than with placebo (34% versus 11%, respectively; P=0.0002). Conclusions: In this randomized, placebo-controlled trial, oral administration of high-dose colchicine at the time of reperfusion and for 5 days did not reduce IS assessed by cardiac magnetic resonance imaging. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03156816.